1. Traycoff CM, Kosak ST, Grigsby S, Srour EF. Evaluation of ex vivo expansion potential of cord blood and bone marrow Hematopoietic progenitor cells using cell tracking and limiting dilution analysis. Blood. 1995; 85:2059-68.

2. Sandstrom CE, Bender JG, Papoutsakis ET, Miller WM. Effects of CD34/+/ cell selection and perfusion on ex vivo expansion of peripheral blood mono nuclear cells. Blood. 1995; 86:958-70.

3. Moore MAS. Expansion of myeloid stem cells in culture. Seminars in Hematology. 1995; 32:183-200.

4. Verfaillie CM.Direct contact between human primitive Hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood. 1992; 79:2821-6.

5. Koller MR, Paisson MA, Manchel I, Paisson BO. Long-term culture-initiating cell expansion is dependent on frequent medium exchange combined with stromal and other accessory cell effects. Blood. 1995; 86:1784-93.

6. Koller MR, Bender JG, Papoutsakis ET, Miller WM. Effects of synergistic cytokine combinations, low oxygen, and irradiated stroma on the expansion of human cord blood progenitors. Blood. 1992; 80:403-11.

7. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34/+/ cells into the myeloid lineage. Blood. 1992; 80:1405-12.

8. Rafii S. Shapiro, F, Pettengell R, et al. Human bone marrow micro vascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood. 1995; 86:3353-63.

9. McKenna HJ, De Vries P, Brasel K, Lyman SD, Williams DE. Effect of flt3Ligand on the ex vivo expansion of human CD34/+/ Hematopoietic progenitor cells. Blood. 1995; 86:3413-20.

10. Srour EF, Brandt JE, Briddell RA, Grigsby S, Leemhuis T, Hoffman R. Long-term generation and expansion of human primitive Hematopoietic progenitor cells in vitro. Blood. 1993; 81:661-9.

11. Koller MR, Bender JG, Miller WM, Papoutsakis ET. Expansion of primitive human Hematopoietic progenitors in a perfusion bioreactor system with IL-3, IL-6, and stem cell factor. Bio Technology. 1993; 11:358-63.

12. Brandt JE, Briddel RA, Sr our EF, Leemhuis TB, Hoffman R. Role of c-kit Ligand in the expansion of human Hematopoietic progenitor cells. Blood. 1992;79-634

13. Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Ex vivo expansion of enriched peripheral blood CD34/+/ progenitor cells by stem cell factor, interleukin-1b (IL-1b), IL-6, IL-3, interferon-gamma, and Erythropoietin. Blood. 1993; 81:2579-84.

14. Koller MR, Emerson SG, Paisson BO. Large-scale expansion of human stem and progenitor cells from bone marrow mono nuclear cells in continuous perfusion cultures. Blood. 1993; 82:378-84.

15. Verfaillie CM, Catanzarro PM, Li W. Macrophage inflammatory protein1a, interleukin 3 and d if fusible marrow stromal factors maintain human Hematopoietic stem cells for at least eight weeks in vitro. J Exp Med. 1994; 179:643-9.

16. Coutinho LH, Will A, Rad ford J, Schiro R, Test a NG, Dexter TM. Effects of recombinant human granulocyte colony-stimulating factor (CSF), human granulocyte macrophage-CSF, and Gibbon interleukin-3 on hematopoiesis in human long-term bone marrow culture. Blood. 1990; 75:2118-29.

17. Shapiro F, Yao T-J, Rapt is G, Reich L, Norton L, Moore MAS. Optimization of conditions for ex vivo expansion of CD34/+/ cells from patients with stage IV breast cancer. Blood. 1994; 84:3567-74.

18. B rugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. NEJM. 1995; 333:283-7.

19. Champlin RE, Mehra R, Gajewski J, et al. Ex vivo expanded progenitor cell transplantation in patients with breast cancer. Blood. 1995; (in press): (abs)

20. Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high dose versus standard FAC chemotherapy for advanced breast cancer in protected environment unit: a prospective randomized study. J Clin Oncol. 1987; 5:354-64.

21. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer. 1994;74 Suppl.416-23.

22. Aisner J, Cirrinci one C, Perl off M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol. 1995; 13:1443-52.

23. Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol. 1995;22 Suppl. 5:5-21.

24. Henderson IC. Chemotherapy for advanced disease. In: Harris JR, Hellmans Henderson IC, Kinne DW, eds. Breast Diseases. Philadelphia: JB Lippincott; 1987:428-79.

25. Cheson BD. Bone marrow transplant trials for breast cancer. Oncology. 1991; 5:55-62.

26. Ant man K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carbo plat in with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin Oncol. 1992; 10:102-10.

27. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol. 1992; 10:657-70.

28. Broun ER, Sridhara R, Sledge GW, et al. Tandem auto transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology. 1995; 13:2050-5.

29. Ant man K, Cor ring ham R, De Vries E, et al. Dose intensive therapy in breast cancer. Bone Marrow Transplant. 1992;10 Suppl. 1:67-73.

30. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with Hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. Journal of Clinical Oncology. 1995; 13:2483-9.

31. Rosti G, Las set C, Albertazzi L, et al. The EBMT data on high-dose chemotherapy in breast cancer. Bone Marrow Transplant. 1992;10 Suppl. 2:37

32. Hryniuk WM, Bush H, The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2:1281-7.

33. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993; 11:1132-43.

34. Vaughan WP. Autologous bone marrow transplantation in the treatment of breast cancer: Clinical and technologic strategies. Semi n Oncol. 1993;20 Suppl. 6:55-8.

35. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol. 1994; 12:37-44.

36. Crown J, Vahdat L, Vennelly D, et al. High-intensity chemotherapy with Hematopoietic support in breast cancer. Ann NY Acad Sci. 1993; 698:378-88.

37. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990; 8:1207-16.

38. Hortobagyi GN, Dunphy F, Buzdar AU, Spitz er G. Dose intensity studies in breast cancer-Autologous bone marrow transplantation. Prog Clin Biol Res. 1990;354B:195-209.

39. Peters WP, Shpall EJ, Jones RB, et al. High Dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988; 6:1368-76.

40. Teicher B, Cucchi C, Lee J, et al. alkylating agents. In vitro studies of cross-resistence patterns in human tumor cell lines. Cancer Res. 1986; 46:4379-83.

41. Williams SF, Bit ran JD, Kaminer l, et al. A phase 1-II study of bialkylator chemotherapy high-dose thiotepa and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol. 1987; 5:260-5.

42. Eder JP, Antman K, Elias A, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. JNCI. 1988; 80:1221-6.

详文见附件